Hongming Li
About Hongming Li
Hongming Li is the Director of Discovery Process Chemistry at Alkermes in Waltham, Massachusetts, with over 15 years of experience in the pharmaceutical industry.
Title
Hongming Li holds the position of Director, Discovery Process Chemistry at Alkermes in Waltham, Massachusetts, United States. In his role, he is actively involved in leading drug development projects and fostering a collaborative research environment.
Company
Currently, Hongming Li is employed at Alkermes, a company known for its work in the field of pharmaceutical development focused on CNS disorders and oncology. At Alkermes, Li brings his extensive experience in process chemistry and drug discovery to drive the company's research initiatives.
Previous Experience at Merck
Prior to joining Alkermes, Hongming Li worked at Merck for a total of 11 years. He served as an Associate Principal Scientist from 2013 to 2021 and as a Senior Scientist from 2009 to 2012. During his tenure, he contributed to multiple drug development projects, leading to several successful clinical candidates.
Education and Expertise
Hongming Li earned his Ph.D. in Chemistry from Brandeis University, where he studied from 2001 to 2006. He also attended SIOC (Shanghai Institute of Organic Chemistry). With over 15 years of experience in the pharmaceutical industry, Li has focused extensively on process chemistry and drug discovery.
Research Contributions and Publications
Hongming Li has published numerous research papers in peer-reviewed journals, particularly on topics related to organic chemistry and drug synthesis. His academic and industry research contributions have been recognized internationally, and he often presents his findings at conferences and symposiums.
Mentorship and Collaboration
At Alkermes, Hongming Li actively mentors junior scientists, fostering a collaborative and productive research environment. His mentorship helps in nurturing the next generation of scientists and ensuring the continued success of the company's research endeavors.